Shannon Reaney, Ph.D.

Patent counsel to Genentech in securing valuable patent term extension for numerous approved biologic and small molecule products and assisting the client with numerous IP diligence evaluations for potential investment or licensing opportunitie

Providing strategic patent counseling and prosecution services to Tessera Therapeutics, whose genome engineering technology and proprietary lipid nanoparticles potentially have significant medicinal applications to address major unmet medical needs.

Patent counsel to Maze Therapeutics, Inc. on all aspects of patent strategy and portfolio development for the company’s small molecule programs, including the investigational product MZE001, which was granted Orphan Drug Designation for the treatment of Pompe disease and for which Maze entered into an exclusive worldwide license agreement with Shionogi & Co., Ltd.

Nuvation Bio, Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, has relied on Shannon for patent strategy and advice for protecting its product candidates in development and in assisting the company with IP due diligence in assessing strategic acquisition and licensing opportunities, including its acquisition of AnHeart Therapeutics.

Patent counsel to Pliant Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, including idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

Cerus Corporation, a biotechnology company specializing in blood safety technologies, has long relied on Morrison Foerster for overall patent strategy, including patent application drafting and prosecution. Shannon leads the team that supports Cerus in protecting its commercial and development technologies.